tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Michael Ulz, 113 are a BUY (67.66%), 49 are a HOLD (29.34%), 5 are a SELL (2.99%).
Analyst Michael Ulz, currently employed at MORGAN STANLEY, carries an average stock price target met ratio of 58.61% that have a potential upside of 41.89% achieved within 190 days.
Michael Ulz’s has documented 355 price targets and ratings displayed on 46 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on KPTI, Karyopharm Therapeutics at 12-Aug-2025.
Analyst best performing recommendations are on KPTI (KARYOPHARM THERAPEUTICS).
The best stock recommendation documented was for KPTI (KARYOPHARM THERAPEUTICS) at 8/12/2025. The price target of $25 was fulfilled within 1 day with a profit of $148.85 (85.62%) receiving and performance score of 856.2.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy
$205
$22.5 (12.33%)
4 years 5 months 4 days ago
(04-May-2021)
3/5 (60%)
$35.09 (20.65%)
938
Hold
$173
$-9.5 (-5.21%)
$156
4 years 5 months 6 days ago
(02-May-2021)
14/24 (58.33%)
$2.73 (1.60%)
682
Hold
$190
4 years 5 months 13 days ago
(25-Apr-2021)
9/11 (81.82%)
$34.41 (22.12%)
350
Buy
$175
$-7.5 (-4.11%)
$165
4 years 8 months 5 days ago
(03-Feb-2021)
3/3 (100%)
$19.41 (12.48%)
397
Hold
$166
$-16.5 (-9.04%)
$175
4 years 8 months 5 days ago
(03-Feb-2021)
23/23 (100%)
$10.41 (6.69%)
828
Which stock is Michael Ulz is most bullish on?
Which stock is Michael Ulz is most reserved on?
What Year was the first public recommendation made by Michael Ulz?
